Low-Dose Naltrexone for Joint Pain in Teenage Hypermobility/Connective Tissue Disorder
Low-dose naltrexone (LDN) can be considered as a second- or third-line agent for chronic joint pain in a teenage patient with hypermobility and connective tissue disorder, but only after first-line treatments with NSAIDs, acetaminophen, and neuromodulators (gabapentin, pregabalin, or tricyclic antidepressants) have been tried and proven inadequate.
Treatment Algorithm
First-Line Approach
Start with evidence-based first-line agents for musculoskeletal pain:
- Acetaminophen and NSAIDs are recommended as first-line agents for musculoskeletal pain 1
- Acetaminophen has fewer side effects than NSAIDs and should be considered first
- For neuropathic pain components (common in hypermobility disorders), consider gabapentin or pregabalin as first-line neuromodulators 2
Second-Line Consideration: Low-Dose Naltrexone
If first-line therapies fail to provide adequate relief, LDN may be considered with the following specific regimen:
Dosing Protocol:
- Start at 1.5 mg at bedtime 3
- Titrate upward by 1.5 mg increments every 2 weeks 3
- Target dose range: 1.5-4.5 mg nightly 3, 4
- Maximum dose: 4.5 mg at bedtime 3
Critical Dosing Considerations: The maximally effective dose of LDN is highly idiosyncratic and varies widely between patients 4. Do not use a fixed 4.5 mg dose for all patients—this approach has shown limited efficacy in some studies 5. Instead, titrate slowly to find each patient's optimal dose, which may be anywhere from 1.5 to 4.5 mg 4.
Evidence Quality and Limitations
The evidence for LDN in hypermobility disorders is limited but emerging:
- Neuropathic pain evidence: LDN has demonstrated efficacy in chronic neuropathic pain conditions including fibromyalgia and complex regional pain syndrome 3
- Arthritis evidence is mixed: A 2023 randomized controlled trial showed no benefit for nociceptive arthritis pain 5, but the sample was too small to assess neuropathic or mixed pain patterns
- Chronic pain in general: Recent observational data shows modest pain reduction (average -0.83 on pain scale) with LDN 6, though effects are variable
- Hypermobility-specific data: The 2025 AGA guidelines on hypermobile Ehlers-Danlos syndrome mention neuromodulators (gabapentin, pregabalin, tricyclic antidepressants) for pain management but do not specifically address LDN 7
Mechanism and Rationale
LDN works through antagonism of toll-like receptor 4, reducing pro-inflammatory cytokines and modulating microglial activity—mechanisms relevant to nociplastic pain common in hypermobility disorders 3. This differs from standard naltrexone's opioid receptor antagonism at higher doses (50 mg) 8.
Safety Profile
Common side effects (reported in 32% of patients) 6:
- Vivid dreams (most common)
- Drowsiness
- Dizziness
- Nausea
- Rarely: increased pain (may require discontinuation)
Important safety note: LDN is generally well-tolerated with no serious adverse effects reported in studies 9, 10. However, the FDA-approved dose for opioid/alcohol dependence is 50 mg daily 8—low-dose use (1.5-4.5 mg) is off-label.
Critical Caveats
Avoid opioids: Do not use opioids as first-line therapy for chronic pain in this population 1. Opioids should be avoided specifically for abdominal pain in hypermobility disorders 7
Patient must be opioid-free: If the patient has been on any opioids (including tramadol), they must be opioid-free for 7-10 days minimum before starting naltrexone at any dose 8
Multidisciplinary approach: Pain management should include physical therapy focused on joint stabilization, psychological support for anxiety/distress common in hypermobility 7, 11, and treatment of comorbid dysautonomia if present 7, 12
Duration of trial: Allow 8-12 weeks at target dose to assess efficacy 4, 6, with average treatment duration around 4 months in clinical practice 6
Reassess regularly: If no benefit after adequate trial at maximum tolerated dose, discontinue and consider alternative neuromodulators or referral to pain specialist 2
Practical Implementation
Monitor for hormesis effect: Some patients may experience worsening pain at certain doses during titration, then improvement at higher or lower doses—this hormetic response pattern requires flexible dose adjustment 4.
Set realistic expectations: Average pain reduction is modest (typically 1-2 points on 0-10 scale) 6, but some patients report substantial benefits including improved quality of life, reduced pain flares, better sleep, and ability to discontinue other pain medications 10.